Rentschler Biopharma, as a leading global CDMO for biopharmaceuticals, ensures optimum time to proof-of-concept for products in clinical stages I and II, as well as time-to-market for clinical stage III.
In the face of the current pandemic, the rapid evaluation of protein-based vaccines and therapeutics is more important than ever before. Moreover, it is essential that the advantages of shortened timelines reach patients without increasing their risk profile during clinical trials. To achieve that, we apply a holistic approach by planning for commercial biomanufacturing during - not following - clinical development. That is key to maximizing patient benefit.
To learn more about Rentschler Biopharma optimizes time-to-market for life-saving biopharmaceuticals, download our capabilities review in the latest BPI Industry Innovators Issue.